McCourt Marion 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Aug 5, 2024
Insider Transaction Report
Form 4
McCourt Marion
SVP Commercial
Transactions
- Exercise/Conversion
Common Stock
2024-08-01$372.46/sh+1,137$423,487→ 14,068 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-08-01−1,137→ 0 totalExercise: $372.46Exp: 2029-12-11→ Common Stock (1,137 underlying) - Sale
Common Stock
2024-08-01$1060.86/sh−1,137$1,206,198→ 12,931 total
Holdings
- 174(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024.
- [F2]The stock option award vests in four equal annual installments, commencing one year after the date of grant.